NLS Pharmaceutics Ltd.

Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Feb 27, 2025

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 25, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 10, 2025

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Jan 31, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 28, 2025

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 16, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Dec 30, 2024

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

Dec 04, 2024

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Jan 28, 2021

NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering